Thanks. From the Lancet oncology article, there does appear to be a a slight survival advantage of the 10 mg/kg over 3 mg/kg. This must have made it easy to "turf" the gp100 + 3 mg/kg ipi trial.
Excerpt: Table 2 shows effi cacy data for every treatment group. As the dose of ipilimumab increased, best overall response rate rose (p=0·0015, trend test). Survival data are presented in table 2 and fi gure 2. Hazard ratios for comparisons of median overall survival between groups were as follows: 10 mg/kg versus 0·3 mg/kg, 0·770 (95% CI 0·525–1·130); 10 mg/kg versus 3 mg/kg, 0·875 (0·593–1·291); and 3 mg/kg versus 0·3 mg/kg, 0·879 (0·604–1·279). Subgroup analyses of best overall response rate and overall survival, according to stratifi cation criteria, were consistent with the main analyses (data not shown).
Excerpt:
The final population pharmacokinetic analysis provided an adequate description of ipilimumab serum concentration–time profi les (fi gure 3A). Model-based simulation to assess achievement of the target trough concentration of 20 µg/mL before the fourth (and last) dose in the induction phase indicated that the target concentration was expected to be exceeded by about 95% of patients in the 10 mg/kg group, but by only 30% and 0% in the 3 mg/kg and 0·3 mg/kg groups, respectively (fi gure 3B).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.